Conclusions-Compliance is greater with nose mask CPAP than with face mask CPAP because the overall comfort is better and compensates for increased symptoms associated with mouth leakage. Improved face mask design is needed. (Thorax 1998;53:290-292) Keywords: continuous positive airway pressure; sleep apnoea/hypopnoea syndrome; face masks Continuous positive airway pressure (CPAP) therapy for sleep apnoea/hypopnoea syndrome (SAHS) is traditionally given via a nose mask. However, many patients with SAHS find this method of treatment unsatisfactory, often due to symptoms related to mouth air leakage.
Continuous positive airway pressure (CPAP) therapy for sleep apnoea/hypopnoea syndrome (SAHS) is traditionally given via a nose mask. However, many patients with SAHS find this method of treatment unsatisfactory, often due to symptoms related to mouth air leakage. 1 Patients who have had unsuccessful uvulopalatopharyngoplasties (U3P) for treatment of SAHS are particularly likely to experience increased mouth leakage on nasal CPAP which is associated with reduced nightly compliance. 2 The CPAP pressure required is essentially the same for nose masks and face masks, 3 so face masks which cover both nose and mouth may be advantageous if they reduce the symptoms associated with mouth leakage.
We have compared nose and face mask CPAP therapy with respect to side eVects from the mask and compliance in newly diagnosed patients with SAHS in a randomised double limb trial. We also compared nose and face mask CPAP in patients with unsuccessful uvulopalatopharyngoplasties for treatment of SAHS (SAHS/U3P patients).
Methods
All subjects gave informed consent to take part in the study.
RANDOMISED TRIAL
Twenty consecutive newly diagnosed patients with SAHS (mean (SE) apnoea/hypopnoea index 34 (5.2)/hour, age 52 (3) years, body mass index 32 (1) kg/m 2 , CPAP pressure 9 (1) cm H 2 O) were enrolled into the study after their CPAP titration night. Initial CPAP titration was performed using a nose mask. Patients were randomised to face mask or nose mask CPAP for four weeks each. At the end of each limb subjects were asked to complete a questionnaire on side eVects relating to the mask (10 cm visual analogue scale) and the Epworth sleepiness score. 4 CPAP compliance was also assessed covertly as CPAP machine (Sullivan III, Resmed, Sydney, Australia) run time (hours/night).
NON-RANDOMISED TRIAL
Ten SAHS patients with U3P (mean (SE) apnoea/hypopnoea index 46 (10)/hour, age 50 (3) years, body mass index 31 (4) kg/m 2 , CPAP pressure 10.5 (1) cm H 2 O) who had recently started nose mask CPAP therapy were oVered face mask treatment for four weeks. Prior to starting face mask CPAP patients completed the symptom questionnaire and compliance with nose mask CPAP was measured. At the end of the face mask trial period they completed the symptom questionnaire and CPAP compliance was calculated.
COMPARISON OF LONG TERM COMPLIANCE
Ten patients with SAHS from the randomised trial were matched with the 10 SAHS/U3P patients for age (p = 0.3), body mass index (p = 0.6), apnoea/hypopnoea index (p = 0.2), and CPAP pressure (p = 0.3). These patients were followed up for one year after the randomised and non-randomised trials so that long term compliance could be assessed.
MASKS
Patients were oVered either Resmed (Sydney, Australia) or Respironics (Pennsylvania, USA) nose masks. Face masks were Respironics. Masks were fitted/sized in the laboratory and patients were given a day time trial of CPAP for approximately 40 minutes in order to facilitate mask choice.
FOLLOW UP All patients were followed up in the sleep clinic/laboratory after CPAP titration using the same protocol by staV who were unaware of the trials. Additional supportive measures including changing mask sizes were taken if appropriate during follow up in an eVort to maximise compliance.
ANALYSIS OF RESULTS
Comparisons were made using t tests or Wilcoxon matched pairs signed rank tests as appropriate.
Results

RANDOMISED TRIAL
Median nose and face mask questionnaire symptom scores are shown in table 1. Nightly compliance by patients with SAHS was higher with a nose mask (5.3 (0.4) hours/night) than with a face mask (4.3 (0.5) hours/night), p = 0.01 (mean diVerence 1 hour/night, 95% CI 1.8 to 0.3) and the Epworth score was lower with nose mask CPAP (nose mask 8.2 (0.9) and face mask 9.8 (0.9), p<0.01). Face masks were rated more comfortable by only one of the 20 subjects.
NON-RANDOMISED TRIAL
Questionnaire symptom scores with nose and face masks for SAHS/U3P patients are shown in table 1. Nightly compliance was higher with nose masks (5.1 (0.7) hours/night) than with full face masks (4.0 (0.8) hours/night), but the diVerence was not statistically significant, p = 0.07 (mean diVerence 1.1 hour/night, 95% CI 2.1 to 0.1). The Epworth score was no different between nose and face masks (face mask 10 (2), nose mask 9 (1), p = 0.9). Full face masks were rated more comfortable by three of the 10 subjects.
COMPARISON OF LONG TERM COMPLIANCE
At one year one patient from each group had stopped using CPAP. All nine patients with SAHS on CPAP therapy were using a nose mask and only one of the SAHS/U3P patients was using a full face mask. Compliance was 5.4 (0.6) hours/night for the SAHS patients and 3.5 (0.4) hours/night for the SAHS/U3P patients, p = 0.02 (mean diVerence 1.9 hours/ night, 95% CI 3.6 to 0.3).
There were no significant weight changes in any of the groups during the trial periods.
Discussion
Overall, for the 20 SAHS patients face mask use significantly reduced complaints of dry mouth/nose but at the expense of more problems associated with air leaks from around the edge of the mask and increased feelings of claustrophobia. Nose masks were rated significantly more comfortable than face masks with 19 patients with SAHS preferring nose mask CPAP therapy. The lone patient preferring face mask CPAP had significant problems with mouth leakage using nose masks.
Three of 10 SAHS/U3P patients preferred face mask CPAP therapy. Symptoms of mouth leakage were marginally reduced by face masks compared with nose masks (table 1) but symptoms associated with mask comfort were worse and presumably contributed to the overall mask preference. In addition, most of the patients had been on nose mask CPAP therapy for longer than the four weeks of the face mask trial which probably served to enhance the rating of the nose masks.
After one year of follow up all the SAHS patients had used nose masks exclusively and demonstrated significantly better compliance than matched SAHS/U3P patients which is consistent with our previous findings. 4 Eight of nine SAHS/U3P patients used nose masks exclusively during this period. There were no incentives to enter the trials and SAHS/U3P patients were not aware of CPAP therapy at the time of operation and therefore were not initially biased against CPAP therapy.
We conclude that, despite the potential advantages of face masks in terms of reduction in mouth leak associated symptoms, nose masks are more comfortable than currently available face masks and overall symptom scores are therefore better with nose masks. Face mask CPAP therapy is, however, a useful alternative in a few patients. Face mask use does not seem to resolve completely the problem of decreased CPAP compliance in SAHS/ U3P patients. Improved face mask design in future may overcome this limitation. Reduced mortality in association with the acute respiratory distress syndrome (ARDS) The acute respiratory distress syndrome (ARDS) in adults is characterised by refractory hypoxaemia in the presence of radiographic evidence of bilateral pulmonary infiltration. ARDS may be precipitated by a number of direct and indirect pulmonary insults. A survey of the relevant literature suggests that little change occurred in the high associated mortality (40-80%) from 1967 when the syndrome was first formally described 1 until approximately 1994. 2 Moreover, certain precipitating conditions such as generalised sepsis and primary pulmonary disease are associated with a higher mortality than others such as trauma and fat emboli. Nevertheless, other recent studies suggest that the mortality associated with ARDS has fallen in certain centres 3 and that improved modes of ventilatory support may be a major contributing factor to improved outcome. 4 Our previously published data 5 concerning outcome in ARDS represent the only sizable UK series from a tertiary referral centre and indicated a mortality of 66% from 1990 to April 1993. In view of the suggestion that modern approaches to the clinical management of this condition have made an impact on the mortality associated with ARDS, we have reassessed our outcome data in patients admitted to our unit from June 1993. Direct comparisons were made with our previously published data to assess whether there has been a change in mortality or factors predictive of outcome.
Methods
PATIENT POPULATION
Patients were enrolled prospectively from 1990 to 1997. They were divided into two groups: group 1 (n = 41) enrolled between May 1990 and April 1993 5 and group 2 (n = 78) enrolled from June 1993 to March 1997. The referral basis of the two groups was identical with 21 of 41 patients (51%) in group 1 and 40 of 78 (51%) in group 2 being referred from other centres.
The enrolment criteria were as follows. Briefly, a clinical condition associated with ARDS was identified in the presence of bilateral pulmonary infiltrates on chest radiography. In group 1 refractory hypoxaemia was defined as a ratio of arterial oxygen tension to fractional inspired oxygen concentration (PaO 2 / FIO 2 (kPa)) of <20. Following the publication of the Consensus Guidelines criteria for the definition of ARDS in 1994 6 a PaO 2 /FIO 2 ratio of <26.7 was used for patients in group 2. In both groups the pulmonary artery occlusion pressure (PAOP) was required to be less than 18 mm Hg. In all cases lung injury (LIS, according to the criteria of Murray 7 ) and acute physiology and chronic health evaluation (APACHE II) scores were recorded on the day of admission or on the day on which ARDS was diagnosed and were calculated from the worst values obtained within the first 24 hours. Organ system failures were defined according to the criteria of Montgomery et al, 8 and sepsis was defined according to the consensus criteria published in 1992. 9 CLINICAL MANAGEMENT All patients were managed with mechanical ventilation (Drager Evita I or II, Drager UK Ltd, Luton, Bedfordshire, UK) using a balloon tipped pulmonary artery catheter of the thermodilution type. The mode of ventilation employed at the time of most severe lung injury was noted. The presence or absence of sepsis (defined according to the criteria of the ACCP/SCCM 7 ) and organ dysfunction were noted. Mortality was defined as death in hospital.
STATISTICAL ANALYSIS
Data are presented as mean (SE) throughout. Statistical analysis was performed using Fisher's exact test or the unpaired t test with p values equal to or less than 0.05 being considered significant.
Results
There were no significant diVerences between the two groups in terms of age (40.6 (3. The case mix of the two groups was closely matched (postoperative 48% versus 48%, trauma 17% versus 16%, primary lung injury 12% versus 24% for groups 1 and 2, respectively, p = 0.23). Patients in group 1 were ventilated using several diVerent modes (volume preset, non-inverse ratio, n = 15; pressure controlled, PC-IRV, n = 11; ultra high frequency jet ventilation (UHFJV), n = 13; extracorporeal or intracorporeal gas exchange (ECGE), n = 2). All the patients in group 2 received PC-IRV but, in addition, some received other support techniques (UHFJV, n = 4; ECGE, n = 2).
There was a highly significant reduction in mortality between patients in group 1 (66%) and group 2 (34%; p = 0.0037; relative risk, 1.77; CI 1.23 to 2.55).
In group 1 the presence of sepsis on admission, seen in 21% of survivors and 56% of non-survivors, was the sole predictor of death (p = 0.05). No significant diVerence in mortality was observed between patients receiving volume-controlled ventilation and the remainder. In group 2 age (41.2 (2.6) versus 52.6 (3.5), p = 0.01), APACHE II score (12.2 (0.6) versus 15.8 (0.9), p = 0.001), and PaO 2 /FIO 2 (12.8 (0.86) versus 10.5 (0.72), p = 0.04) for survivors and non-survivors, respectively, were significant predictors of survival. Sepsis (survivors 47% versus non-survivors 
